IMBiologics transfers autoimmune illness drug know-how to Huadong Pharma

South Korean antibody biotech firm IMBilogics introduced on Friday that it has signed a contract to switch the know-how of its autoimmune illness remedy candidate to China’s Huadong Pharmaceutical.

The contract consists of an upfront fee of $8 million, with potential milestone funds of as much as $375 million.

The substances being transferred by IMBilogics embrace two candidates: the bispecific antibody candidate IMB-101, which targets the autoimmune illness antibody OX40L and tumor necrosis issue (TNF), and the monospecific antibody IMB-102, which concentrating on solely OX40L.

These substances have been collectively developed by three home firms: IMBilogics, HK inno.N and Y Biologics.

Underneath the contract, Huadong Pharmaceutical could have the rights to develop and commercialize these candidate substances in Asia, excluding South Korea, North Korea and Japan.

Huadong Pharmaceutical, one of many high 10 pharmaceutical firms in China, is a subsidiary of Huadong Medication Co, Ltd. IMBiologics stated the corporate is at the moment creating antibodies for immune problems, biosimilars, and different merchandise as a part of its pipeline.

In June, IMBilogics additionally signed a contract to switch IMB-101 and IMB-102 know-how to US drug developer Navigator Medicines. That contract was bought for a complete of $944.8 million, together with an upfront fee.

Write to Yoo-Rim Kim at youforest@hankyung.com